Nutritional Status Impairment Due to Neoadjuvant Chemotherapy Predicts Post-Radical Cystectomy Complications.


Journal

Nutrients
ISSN: 2072-6643
Titre abrégé: Nutrients
Pays: Switzerland
ID NLM: 101521595

Informations de publication

Date de publication:
14 Dec 2021
Historique:
received: 10 11 2021
revised: 10 12 2021
accepted: 13 12 2021
entrez: 28 12 2021
pubmed: 29 12 2021
medline: 13 1 2022
Statut: epublish

Résumé

Radical cystectomy (RC) is the standard treatment for muscle invasive bladder cancer (MIBC). Neoadjuvant chemotherapy (NAC) is associated with improved patient survival. The impact of NAC on nutritional status is understudied, while the association between malnutrition and poor surgical outcomes is well known. This study aims to examine the association between NAC, nutritional status impairment, and post-operative morbidity. We included MIBC patients who underwent RC and received NAC from multiple academic centers in Israel. Cross-sectional imaging was used to measure the psoas muscle area and normalized it by height (smooth muscle index, SMI). Pre- and post-NAC SMI difference was calculated (represents nutritional status change). The primary outcomes were post-RC ileus, infection, and a composite outcome of any complication. Logistic regression models were fit to identify independent predictors of the outcomes. Ninety-one patients were included in the study. The median SMI change was -0.71 (-1.58, -0.06) cm NAC-related nutritional deterioration is associated with increased risk of complications after RC. Our results hint towards the need for nutritional intervention during NAC prior to RC.

Sections du résumé

BACKGROUND BACKGROUND
Radical cystectomy (RC) is the standard treatment for muscle invasive bladder cancer (MIBC). Neoadjuvant chemotherapy (NAC) is associated with improved patient survival. The impact of NAC on nutritional status is understudied, while the association between malnutrition and poor surgical outcomes is well known. This study aims to examine the association between NAC, nutritional status impairment, and post-operative morbidity.
MATERIALS AND METHODS METHODS
We included MIBC patients who underwent RC and received NAC from multiple academic centers in Israel. Cross-sectional imaging was used to measure the psoas muscle area and normalized it by height (smooth muscle index, SMI). Pre- and post-NAC SMI difference was calculated (represents nutritional status change). The primary outcomes were post-RC ileus, infection, and a composite outcome of any complication. Logistic regression models were fit to identify independent predictors of the outcomes.
RESULTS RESULTS
Ninety-one patients were included in the study. The median SMI change was -0.71 (-1.58, -0.06) cm
CONCLUSIONS CONCLUSIONS
NAC-related nutritional deterioration is associated with increased risk of complications after RC. Our results hint towards the need for nutritional intervention during NAC prior to RC.

Identifiants

pubmed: 34960023
pii: nu13124471
doi: 10.3390/nu13124471
pmc: PMC8708207
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Eur Urol Oncol. 2019 Jul;2(4):443-447
pubmed: 31277781
Cancer. 1979 May;43(5 Suppl):2036-52
pubmed: 109184
Can Urol Assoc J. 2017 Dec;11(12):419-424
pubmed: 29106362
Clin Nutr. 2017 Dec;36(6):1473-1482
pubmed: 28017447
BJU Int. 2014 Jun;113(6):918-23
pubmed: 24053616
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
J Urol. 2011 Jan;185(1):90-6
pubmed: 21074802
Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Mar 25;21(3):331-335
pubmed: 29577223
Front Physiol. 2017 Feb 15;8:87
pubmed: 28261109
Strahlenther Onkol. 2013 Sep;189(9):745-52
pubmed: 23896631
ANZ J Surg. 2019 May;89(5):509-514
pubmed: 30959573
Bladder Cancer. 2018 Oct 29;4(4):377-388
pubmed: 30417048
Eur Urol. 2005 Aug;48(2):202-5; discussion 205-6
pubmed: 15939524
Food Nutr Res. 2008;52:
pubmed: 19158940
Cancer. 2014 Sep 15;120(18):2910-8
pubmed: 24840856
World J Urol. 2015 Aug;33(8):1129-37
pubmed: 25240535
Proc Nutr Soc. 2016 May;75(2):199-211
pubmed: 26786393
Nutr Cancer. 2017 Nov-Dec;69(8):1196-1204
pubmed: 29083243
Fam Med Community Health. 2020 Feb 16;8(1):e000262
pubmed: 32148735
Ann Surg Oncol. 2018 Oct;25(11):3365-3371
pubmed: 30097739
Support Care Cancer. 2001 Nov;9(8):575-80
pubmed: 11762967
J Urol. 2014 Jun;191(6):1714-20
pubmed: 24423437
Support Care Cancer. 1993 Nov;1(6):326-30
pubmed: 8156251
Eur Urol. 2017 Mar;71(3):462-475
pubmed: 27375033

Auteurs

Sharon Cohen (S)

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan 5266202, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.

Jonathan Gal (J)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Department of Urology, Shamir Medical Center, Tzrifin 7073001, Israel.

Yuval Freifeld (Y)

Department of Urology, Carmel Medical Center, Haifa 3436212, Israel.
Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa 3109601, Israel.

Sobhi Khoury (S)

Department of Urology, Carmel Medical Center, Haifa 3436212, Israel.
Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa 3109601, Israel.

Yoram Dekel (Y)

Department of Urology, Carmel Medical Center, Haifa 3436212, Israel.
Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa 3109601, Israel.

Azik Hofman (A)

Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa 3109601, Israel.
Department of Urology, Rambam Medical Center, Haifa 3109601, Israel.
Israel Urologic Oncology Collaboration, Petah-Tikva 4941492, Israel.

Kamil Malshi (K)

Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa 3109601, Israel.
Department of Urology, Rambam Medical Center, Haifa 3109601, Israel.

Gilad Amiel (G)

Rappaport Faculty of Medicine, Technion, Israel Institute of Technology, Haifa 3109601, Israel.
Department of Urology, Rambam Medical Center, Haifa 3109601, Israel.
Israel Urologic Oncology Collaboration, Petah-Tikva 4941492, Israel.

Itay Sagi (I)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Israel Urologic Oncology Collaboration, Petah-Tikva 4941492, Israel.
Department of Urology, Meir Medical Center, Kfar Sab 4428164, Israel.

Ilan Leibovici (I)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Department of Urology, Meir Medical Center, Kfar Sab 4428164, Israel.

Shay Golan (S)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Israel Urologic Oncology Collaboration, Petah-Tikva 4941492, Israel.
Department of Urology, Rabin Medical Center, Petah-Tikva 4941492, Israel.

Jack Baniel (J)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Department of Urology, Rabin Medical Center, Petah-Tikva 4941492, Israel.

Barak Rozenzweig (B)

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan 5266202, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Israel Urologic Oncology Collaboration, Petah-Tikva 4941492, Israel.

Zohar Dotan (Z)

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan 5266202, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.

Miki Haifler (M)

Department of Urology, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan 5266202, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Israel Urologic Oncology Collaboration, Petah-Tikva 4941492, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH